IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

(2018) Rizwan Romee et al.   BLOOD

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)

(2018) Todd A. Fehniger et al.   CANCER RESEARCH

IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56 bright NK Cells and Increases NK-Cell Cytokine Release Capabilities

(2017) Sigrid Dubois et al.   Cancer Immunology Research

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

(2016) Jae H. Park et al.   BLOOD

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

(2016) Rony Dahan et al.   CANCER CELL

Anti-PD-1 therapy in the frontline

(2016) David Killock   Nature Reviews Clinical Oncology

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

(2015) M. Rosario et al.   CLINICAL CANCER RESEARCH

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

(2015) Kevin C. Conlon et al.   JOURNAL OF CLINICAL ONCOLOGY

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions

(2015) D. J. DiLillo et al.   Cancer Immunology Research

Rituximab: modes of action, remaining dispute and future perspective

(2014) Abdulmunem Abulayha et al.   Future Oncology

Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action

(2014) S. Dubois et al.   JOURNAL OF IMMUNOLOGY

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse

(2014) Marie Vincent et al.   mAbs

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Consequences of the crosstalk between monocytes/macrophages and natural killer cells

(2013) Tatiana Michel et al.   Frontiers in Immunology

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients

(2012) María P. Roberti et al.   BREAST CANCER RESEARCH AND TREATMENT

Augmented IL-15R  Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice

(2012) M. Zhang et al.   JOURNAL OF IMMUNOLOGY

Macrophages Help NK Cells to Attack Tumor Cells by Stimulatory NKG2D Ligand but Protect Themselves from NK Killing by Inhibitory Ligand Qa-1

(2012) Zhixia Zhou et al.   PLoS One

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model

(2012) P. Yu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques

(2011) T. A. Waldmann et al.   BLOOD

IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood

(2011) M. C. Sneller et al.   BLOOD

Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression

(2011) Esther Moga et al.   EXPERIMENTAL HEMATOLOGY

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates

(2010) E. Lugli et al.   BLOOD

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model

(2010) P. Yu et al.   CLINICAL CANCER RESEARCH

Activating and inhibitory receptors of natural killer cells

(2010) Hollie J Pegram et al.   IMMUNOLOGY AND CELL BIOLOGY

Fc RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo

(2010) F. Nimmerjahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma

(2009) M Watanabe et al.   BRITISH JOURNAL OF CANCER

Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

(2009) M. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

(2008) Jacob A. Klapper et al.   CANCER